Published in Infect Immun on June 01, 2006
A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci U S A (2010) 2.90
Immune defense against pneumonic plague. Immunol Rev (2008) 1.44
The metalloregulatory zinc site in Streptococcus pneumoniae AdcR, a zinc-activated MarR family repressor. J Mol Biol (2010) 1.25
Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis. Infect Immun (2007) 1.15
Development of Burkholderia mallei and pseudomallei vaccines. Front Cell Infect Microbiol (2013) 1.08
Phenotypic and functional characterization of human memory T cell responses to Burkholderia pseudomallei. PLoS Negl Trop Dis (2009) 1.05
Vaccination of mice with a Yop translocon complex elicits antibodies that are protective against infection with F1- Yersinia pestis. Infect Immun (2008) 1.00
Analysis of the protective capacity of three Streptococcus suis proteins induced under divalent-cation-limited conditions. Infect Immun (2008) 0.99
Interaction between Yersinia pestis and the host immune system. Infect Immun (2008) 0.98
Characterization and evaluation of the Moraxella catarrhalis oligopeptide permease A as a mucosal vaccine antigen. Infect Immun (2010) 0.96
A member of the second carbohydrate uptake subfamily of ATP-binding cassette transporters is responsible for ribonucleoside uptake in Streptococcus mutans. J Bacteriol (2006) 0.93
High-throughput identification of new protective antigens from a Yersinia pestis live vaccine by enzyme-linked immunospot assay. Infect Immun (2009) 0.92
Identification of a Vibrio furnissii oligopeptide permease and characterization of its in vitro hemolytic activity. J Bacteriol (2007) 0.87
Identification of conserved antigens for early serodiagnosis of relapsing fever Borrelia. Microbiology (2009) 0.87
Role of the oligopeptide permease ABC Transporter of Moraxella catarrhalis in nutrient acquisition and persistence in the respiratory tract. Infect Immun (2014) 0.84
Dynamic longitudinal antibody responses during Borrelia burgdorferi infection and antibiotic treatment of rhesus macaques. Clin Vaccine Immunol (2012) 0.84
Identification of Mycobacterium avium genes expressed during in vivo infection and the role of the oligopeptide transporter OppA in virulence. Microb Pathog (2014) 0.82
Analysis of whitefly transcriptional responses to Beauveria bassiana infection reveals new insights into insect-fungus interactions. PLoS One (2013) 0.82
Substrate binding protein SBP2 of a putative ABC transporter as a novel vaccine antigen of Moraxella catarrhalis. Infect Immun (2014) 0.79
An update on the transport and metabolism of iron in Listeria monocytogenes: the role of proteins involved in pathogenicity. Biometals (2015) 0.78
Melioidosis: Clinical impact and public health threat in the tropics. PLoS Negl Trop Dis (2017) 0.76
Expression of the Oligopeptide Permease Operon of Moraxella catarrhalis Is Regulated by Temperature and Nutrient Availability. Infect Immun (2015) 0.75
ATP-Binding Cassette (ABC) Transporters of the Human Respiratory Tract Pathogen, Moraxella catarrhalis: Role in Virulence. PLoS One (2016) 0.75
Identification of a novel Haemophilus parasuis-specific B cell epitope using monoclonal antibody against the OppA protein. PLoS One (2014) 0.75
ABC transporters: from microorganisms to man. Annu Rev Cell Biol (1992) 19.49
Yersinia pestis--etiologic agent of plague. Clin Microbiol Rev (1997) 14.63
Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (2000) 8.45
The ATP switch model for ABC transporters. Nat Struct Mol Biol (2004) 3.58
A Streptococcus pneumoniae pathogenicity island encoding an ABC transporter involved in iron uptake and virulence. Mol Microbiol (2001) 2.55
Uptake of cell wall peptides by Salmonella typhimurium and Escherichia coli. J Bacteriol (1987) 2.18
ATP-binding cassette transporters are targets for the development of antibacterial vaccines and therapies. Infect Immun (2004) 2.15
Vaccination against bubonic and pneumonic plague. Vaccine (2001) 2.08
A comparison of Plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model. Vaccine (1995) 2.03
Oligopeptide permease is required for expression of the Bacillus thuringiensis plcR regulon and for virulence. Mol Microbiol (2001) 1.95
An unusual strain of Pasteurella pestis isolated from a fatal human case of plague. Bull World Health Organ (1960) 1.86
Immunization with components of two iron uptake ABC transporters protects mice against systemic Streptococcus pneumoniae infection. Infect Immun (2001) 1.81
Plague. A clinical review of 27 cases. Arch Intern Med (1992) 1.76
Yersinia pestis (plague) vaccines. Expert Opin Biol Ther (2004) 1.72
A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague. Vaccine (1997) 1.70
Transport of beta-casein-derived peptides by the oligopeptide transport system is a crucial step in the proteolytic pathway of Lactococcus lactis. J Biol Chem (1995) 1.69
Isolation and characterization of toluene-sensitive mutants from the toluene-resistant bacterium Pseudomonas putida GM73. J Bacteriol (1998) 1.68
Structural gene for the phosphate-repressible phosphate-binding protein of Escherichia coli has its own promoter: complete nucleotide sequence of the phoS gene. J Bacteriol (1984) 1.65
An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model. Clin Exp Immunol (1999) 1.57
Plague immunization. II. Relation of adverse clinical reactions to multiple immunizations with killed vaccine. J Infect Dis (1974) 1.52
Specialized peptide transport system in Escherichia coli. J Bacteriol (1975) 1.51
Regulation of peptide transport in Escherichia coli: induction of the trp-linked operon encoding the oligopeptide permease. J Bacteriol (1986) 1.40
A single dose sub-unit vaccine protects against pneumonic plague. Vaccine (2000) 1.35
Plague vaccine research and development. J Appl Microbiol (2001) 1.20
Effects of oligopeptide permease in group a streptococcal infection. Infect Immun (2005) 1.11
Gentamicin and tetracyclines for the treatment of human plague: review of 75 cases in new Mexico, 1985-1999. Clin Infect Dis (2004) 1.00
Tularemia. Clin Microbiol Rev (2002) 8.51
Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc Natl Acad Sci U S A (2004) 7.30
The complete genome sequence of Francisella tularensis, the causative agent of tularemia. Nat Genet (2005) 6.22
Tularaemia: bioterrorism defence renews interest in Francisella tularensis. Nat Rev Microbiol (2004) 5.38
Architecture of succinate dehydrogenase and reactive oxygen species generation. Science (2003) 4.40
Structure and molecular mechanism of a nucleobase-cation-symport-1 family transporter. Science (2008) 3.39
Genome-wide DNA microarray analysis of Francisella tularensis strains demonstrates extensive genetic conservation within the species but identifies regions that are unique to the highly virulent F. tularensis subsp. tularensis. J Clin Microbiol (2003) 3.08
Skewed genomic variability in strains of the toxigenic bacterial pathogen, Clostridium perfringens. Genome Res (2006) 2.84
Structural determination of wild-type lactose permease. Proc Natl Acad Sci U S A (2007) 2.83
Maltose-neopentyl glycol (MNG) amphiphiles for solubilization, stabilization and crystallization of membrane proteins. Nat Methods (2010) 2.77
Absence of Yersinia pestis-specific DNA in human teeth from five European excavations of putative plague victims. Microbiology (2004) 2.75
Molecular basis of proton motive force generation: structure of formate dehydrogenase-N. Science (2002) 2.61
Application of DNA microarrays to study the evolutionary genomics of Yersinia pestis and Yersinia pseudotuberculosis. Genome Res (2003) 2.51
Attenuated virulence and protective efficacy of a Burkholderia pseudomallei bsa type III secretion mutant in murine models of melioidosis. Microbiology (2004) 2.28
ATP-binding cassette transporters are targets for the development of antibacterial vaccines and therapies. Infect Immun (2004) 2.15
A Burkholderia pseudomallei protein microarray reveals serodiagnostic and cross-reactive antigens. Proc Natl Acad Sci U S A (2009) 2.10
Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. J Med Microbiol (2004) 1.82
Molecules incorporating a benzothiazole core scaffold inhibit the N-myristoyltransferase of Plasmodium falciparum. Biochem J (2007) 1.75
Structural insights into the molecular organization of the S-layer from Clostridium difficile. Mol Microbiol (2009) 1.71
From protein microarrays to diagnostic antigen discovery: a study of the pathogen Francisella tularensis. Bioinformatics (2007) 1.68
A genomic survey of positive selection in Burkholderia pseudomallei provides insights into the evolution of accidental virulence. PLoS Pathog (2010) 1.65
Direct repeat-mediated deletion of a type IV pilin gene results in major virulence attenuation of Francisella tularensis. Mol Microbiol (2006) 1.65
Benchmarking membrane protein detergent stability for improving throughput of high-resolution X-ray structures. Structure (2011) 1.62
Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Mol Biochem Parasitol (2003) 1.61
A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infect Immun (2002) 1.60
Role of T cells in innate and adaptive immunity against murine Burkholderia pseudomallei infection. J Infect Dis (2005) 1.56
Clostridium perfringens epsilon-toxin shows structural similarity to the pore-forming toxin aerolysin. Nat Struct Mol Biol (2004) 1.55
Addition of missing loops and domains to protein models by x-ray solution scattering. Biophys J (2002) 1.54
Characterization of the O antigen gene cluster and structural analysis of the O antigen of Francisella tularensis subsp. tularensis. J Med Microbiol (2003) 1.48
Exploiting the Burkholderia pseudomallei acute phase antigen BPSL2765 for structure-based epitope discovery/design in structural vaccinology. Chem Biol (2013) 1.45
The immunologically distinct O antigens from Francisella tularensis subspecies tularensis and Francisella novicida are both virulence determinants and protective antigens. Infect Immun (2006) 1.42
Rethinking our understanding of the pathogenesis of necrotic enteritis in chickens. Trends Microbiol (2008) 1.39
Structural and computational analysis of the quinone-binding site of complex II (succinate-ubiquinone oxidoreductase): a mechanism of electron transfer and proton conduction during ubiquinone reduction. J Biol Chem (2005) 1.38
Discrimination of human pathogenic subspecies of Francisella tularensis by using restriction fragment length polymorphism. J Clin Microbiol (2003) 1.38
Characterisation of an acapsular mutant of Burkholderia pseudomallei identified by signature tagged mutagenesis. J Med Microbiol (2002) 1.37
A type IV pilin, PilA, Contributes To Adherence of Burkholderia pseudomallei and virulence in vivo. Infect Immun (2005) 1.34
Crystal structure of Mycobacterium tuberculosis catalase-peroxidase. J Biol Chem (2004) 1.34
N-myristoyltransferase: a prospective drug target for protozoan parasites. ChemMedChem (2008) 1.33
Genotyping and phenotyping of beta2-toxigenic Clostridium perfringens fecal isolates associated with gastrointestinal diseases in piglets. J Clin Microbiol (2003) 1.32
Characterization and selective inhibition of myristoyl-CoA:protein N-myristoyltransferase from Trypanosoma brucei and Leishmania major. Biochem J (2006) 1.30
Melioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes. PLoS Negl Trop Dis (2012) 1.28
A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection. Vaccine (2011) 1.27
A Burkholderia pseudomallei toxin inhibits helicase activity of translation factor eIF4A. Science (2011) 1.27
Architecture of NarGH reveals a structural classification of Mo-bisMGD enzymes. Structure (2004) 1.26
Dominating IgE-binding epitope of Bet v 1, the major allergen of birch pollen, characterized by X-ray crystallography and site-directed mutagenesis. J Immunol (2003) 1.25
Galleria mellonella as an alternative infection model for Yersinia pseudotuberculosis. Microbiology (2009) 1.23
Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis. Infect Immun (2003) 1.23
Salmonella vaccines for use in humans: present and future perspectives. FEMS Microbiol Rev (2002) 1.22
Humoral and cell-mediated adaptive immune responses are required for protection against Burkholderia pseudomallei challenge and bacterial clearance postinfection. Infect Immun (2005) 1.20
Francisella tularensis vaccines. FEMS Immunol Med Microbiol (2007) 1.19
Macrophage and Galleria mellonella infection models reflect the virulence of naturally occurring isolates of B. pseudomallei, B. thailandensis and B. oklahomensis. BMC Microbiol (2011) 1.19
Melioidosis diagnostic workshop, 2013. Emerg Infect Dis (2015) 1.16
Structural characterization of lipo-oligosaccharide (LOS) from Yersinia pestis: regulation of LOS structure by the PhoPQ system. Mol Microbiol (2002) 1.15
Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis. Infect Immun (2007) 1.15
Four distinct structural domains in Clostridium difficile toxin B visualized using SAXS. J Mol Biol (2010) 1.15
Vaccination strategies for Francisella tularensis. Adv Drug Deliv Rev (2005) 1.15
Towards a Brucella vaccine for humans. FEMS Microbiol Rev (2010) 1.14
Efficacy of the live attenuated Francisella tularensis vaccine (LVS) in a murine model of disease. Vaccine (2005) 1.14
Insect infection model for Campylobacter jejuni reveals that O-methyl phosphoramidate has insecticidal activity. J Infect Dis (2010) 1.13
Characterization and deposition of respirable large- and small-particle bioaerosols. Appl Environ Microbiol (2008) 1.13
Interactions of the type III secretion pathway proteins LcrV and LcrG from Yersinia pestis are mediated by coiled-coil domains. J Biol Chem (2002) 1.12
Global map of growth-regulated gene expression in Burkholderia pseudomallei, the causative agent of melioidosis. J Bacteriol (2006) 1.11
Experimental respiratory anthrax infection in the common marmoset (Callithrix jacchus). Int J Exp Pathol (2008) 1.10
Development of vaccines against burkholderia pseudomallei. Front Microbiol (2011) 1.10
Genome sequencing shows that European isolates of Francisella tularensis subspecies tularensis are almost identical to US laboratory strain Schu S4. PLoS One (2007) 1.09
Oral immunization with a dam mutant of Yersinia pseudotuberculosis protects against plague. Microbiology (2005) 1.08
Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis. Infect Immun (2006) 1.08
Experimental aerogenic Burkholderia mallei (glanders) infection in the BALB/c mouse. J Med Microbiol (2003) 1.07
Characterization of the Burkholderia pseudomallei K96243 capsular polysaccharide I coding region. Infect Immun (2012) 1.07
Immunization with the C-Domain of alpha -Toxin prevents lethal infection, localizes tissue injury, and promotes host response to challenge with Clostridium perfringens. J Infect Dis (2004) 1.06
A Salmonella enterica serovar Typhi vaccine expressing Yersinia pestis F1 antigen on its surface provides protection against plague in mice. Vaccine (2004) 1.06
Oral immunisation with live aroA attenuated Salmonella enterica serovar Typhimurium expressing the Yersinia pestis V antigen protects mice against plague. Vaccine (2003) 1.05
Phenotypic and functional characterization of human memory T cell responses to Burkholderia pseudomallei. PLoS Negl Trop Dis (2009) 1.05
Clostridium absonum alpha-toxin: new insights into clostridial phospholipase C substrate binding and specificity. J Mol Biol (2003) 1.05
Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res (2011) 1.05
Tandem facial amphiphiles for membrane protein stabilization. J Am Chem Soc (2010) 1.05
Formate dehydrogenase--a versatile enzyme in changing environments. Curr Opin Struct Biol (2003) 1.05
Recombinant Bacillus subtilis expressing the Clostridium perfringens alpha toxoid is a candidate orally delivered vaccine against necrotic enteritis. Infect Immun (2008) 1.05
Low-dose exposure of C57BL/6 mice to burkholderia pseudomallei mimics chronic human melioidosis. Am J Pathol (2011) 1.05
The structure of a mixed GluR2 ligand-binding core dimer in complex with (S)-glutamate and the antagonist (S)-NS1209. J Mol Biol (2006) 1.04
The weak interaction of LcrV and TLR2 does not contribute to the virulence of Yersinia pestis. Microbes Infect (2007) 1.04
DNA vaccines: improving expression of antigens. Genet Vaccines Ther (2003) 1.04
Galleria mellonella as an infection model for Campylobacter jejuni virulence. J Med Microbiol (2011) 1.04
Protonmotive force generation by a redox loop mechanism. FEBS Lett (2003) 1.03
Catalytic turnover of [FeFe]-hydrogenase based on single-molecule imaging. J Am Chem Soc (2011) 1.03